Drugmakers have voluntarily recalled more than 580,000 bottles of prazosin hydrochloride capsules nationwide after tests found potential cancer-causing nitrosamine impurities, the U.S. Food and Drug Administration said.
Teva Pharmaceuticals USA, based in New Jersey, and distributor Amerisource Health Services issued the recalls earlier this month for 1 mg, 2 mg, and 5 mg strengths of the blood pressure medication, according to the FDA.
Prazosin relaxes blood vessels to lower blood pressure and is also prescribed for nightmares and sleep issues tied to post-traumatic stress disorder.
The recalled drug is classified as a Class II risk because nitrosamine impurities, which are considered potentially carcinogenic, could form during manufacturing or storage. The recall covers approximately 291,000 bottles distributed nationwide, with affected lots expiring between October 2025 and July 2026, according to FDA records.
